Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters











Publication year range
1.
J Biomed Mater Res A ; 105(4): 1019-1033, 2017 04.
Article in English | MEDLINE | ID: mdl-27943619

ABSTRACT

Demineralized bone matrix (DBM) is a natural, collagen-based, osteoinductive biomaterial. Nevertheless, there are conflicting reports on the efficacy of this product. The purpose of this study was to evaluate whether DBM collagen structure is affected by particle size and can influence DBM cytocompatibility and osteoinductivity. Sheep cortical bone was ground and particles were divided in three fractions with different sizes, defined as large (L, 1-2 mm), medium (M, 0.5-1 mm), and small (S, <0.5 mm). After demineralization, the chemical-physical analysis clearly showed a particle size-dependent alteration in collagen structure, with DBM-M being altered but not as much as DBM-S. DBM-M displayed a preferable trend in almost all biological characteristics tested, although all DBM particles revealed an optimal cytocompatibility. Subcutaneous implantation of DBM particles into immunocompromised mice resulted in bone induction only for DBM-M. When sheep MSC were seeded onto particles before implantation, all DBM particles were able to induce new bone formation with the best incidence for DBM-M and DBM-S. In conclusion, the collagen alteration in DBM-M is likely the best condition to promote bone induction in vivo. Furthermore, the choice of 0.5-1 mm particles may enable to obtain more efficient and consistent results among different research groups in bone tissue-engineering applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 1019-1033, 2017.


Subject(s)
Bone Matrix/cytology , Collagen/chemistry , Mesenchymal Stem Cells/metabolism , Osteogenesis , Animals , Bone Matrix/transplantation , Mice , Mice, SCID , Sheep
2.
Bioconjug Chem ; 25(4): 649-55, 2014 Apr 16.
Article in English | MEDLINE | ID: mdl-24628247

ABSTRACT

Human mesenchymal stem cells (hMSC) are multipotent cells that display the unique ability to home and engraft in tumor stroma. This remarkable tumor tropic property has generated a great deal of interest in many clinical settings. Recently, we showed that hMSC represent an excellent base for cell-mediated anticancer therapy since they are able to internalize paclitaxel (PTX) and to release it in an amount sufficient to inhibit tumor cell proliferation. In order to shed light on the dynamics of drug uptake and release, in the present paper we describe the synthesis of two novel thiophene-based fluorophore-paclitaxel conjugates, namely PTX-F32 and PTX-F35, as tools for in vitro drug tracking. We aimed to study the ability of these novel derivatives to be efficiently internalized by hMSC and, in a properly engineered coculture assay, to be released in the medium and taken up by tumor cells. In order to ensure better stability of the conjugates toward enzymatic hydrolysis, the selected oligothiophenes were connected to the taxol core at the C7 position through a carbamate linkage between PTX and the diamino linker. Antiproliferative experiments on both tumor cells and stromal cells clearly indicate that, in good correlation with the parent compound, cells are sensitive to nanomolar concentrations of the fluorescent conjugates. Moreover, in the coculture assay we were able to monitor, by fluorescence microscopy, PTX-F32 trafficking from hMSC toward glioblastoma U87 tumor cells. Our work paves the way for novel possibilities to perform extensive and high quality fluorescence-based analysis in order to better understand the cellular mechanisms involved in drug trafficking, such as microvescicle/exosome mediated release, in hMSC vehicle cells.


Subject(s)
Drug Delivery Systems , Fluorescent Dyes/analysis , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Paclitaxel/analysis , Paclitaxel/metabolism , Thiophenes/chemistry , Biological Transport , Cell Line, Tumor , Exosomes/metabolism , Fluorescent Dyes/chemistry , Humans , Molecular Conformation , Spectrometry, Fluorescence
3.
J Microsc ; 252(3): 226-50, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24111790

ABSTRACT

Light widefield microscopes and digital imaging are the basis for most of the analyses performed in every biological laboratory. In particular, the microscope's user is typically interested in acquiring high-detailed images for analysing observed cells and tissues, meanwhile being representative of a wide area to have reliable statistics. The microscopist has to choose between higher magnification factor and extension of the observed area, due to the finite size of the camera's field of view. To overcome the need of arrangement, mosaicing techniques have been developed in the past decades for increasing the camera's field of view by stitching together more images. Nevertheless, these approaches typically work in batch mode and rely on motorized microscopes. Or alternatively, the methods are conceived just to provide visually pleasant mosaics not suitable for quantitative analyses. This work presents a tool for building mosaics of images acquired with nonautomated light microscopes. The method proposed is based on visual information only and the mosaics are built by incrementally stitching couples of images, making the approach available also for online applications. Seams in the stitching regions as well as tonal inhomogeneities are corrected by compensating the vignetting effect. In the experiments performed, we tested different registration approaches, confirming that the translation model is not always the best, despite the fact that the motion of the sample holder of the microscope is apparently translational and typically considered as such. The method's implementation is freely distributed as an open source tool called MicroMos. Its usability makes building mosaics of microscope images at subpixel accuracy easier. Furthermore, optional parameters for building mosaics according to different strategies make MicroMos an easy and reliable tool to compare different registration approaches, warping models and tonal corrections.


Subject(s)
Biology/methods , Image Processing, Computer-Assisted/methods , Microscopy/methods , Optical Imaging/methods , Software
4.
Int J Immunopathol Pharmacol ; 26(1 Suppl): 3-9, 2013.
Article in English | MEDLINE | ID: mdl-24046944

ABSTRACT

Mesenchymal stem cells (MSC) and adipose-derived stem cells (ASC) were recently proposed for bone maxillofacial reconstruction in association with biomaterials. For this application MSC must be ex-vivo expanded in order to obtain, for a given volume of implanted biomaterial, a relevant number of bone forming cells. Previously conducted pre-clinical studies suggested that a concentration of 6 x 10(8) ASC associated with 900 mg of anorganic bovine bone (ABB) could be effective for human maxillary sinus floor elevation. A keystone issue to guarantee the quality and safety of Advanced Therapy Medicinal Products containing expanded MSC and ASC is their chromosome stability in culture: this topic has been widely investigated and conflicting results have been published. Abnormal karyotype of human ex-vivo expanded MSC and ASC was found by some authors, while, at the same time, several other studies showed the MSC and ASC karyotype to be normal. It is therefore important that all the results obtained on MSC and ASC karyotype analysis be published. Given this context, the aim of this manuscript, aim of this manuscript is to verify the karyotype stability of ASC in view of their applications in clinical trials. ASC obtained from the adipose tissue of 4 donors were expanded over extended culture time. Based on previous ASC expansions we hypothesized to be able to obtain 6 x 10(8) cells by passage 7. Karyotype analysis of 30 metaphases was planned to be investigated at passage 2, 7, and 15 in all the cultures. No abnormalities were found in the karyotype of two donors at all the passages tested, while a translocation was found in 2 metaphases of a donor at passage 7, but not at passage 15, and in the fourth donor in 5 metaphases a trisomy was found at passage 15. Chromosomal abnormalities were detected only after extended ASC expansion. Whether these anomalies can be related to risk for the patient's safety will have to be demonstrated by in-vivo studies.


Subject(s)
Adipose Tissue/cytology , Karyotype , Plastic Surgery Procedures , Stem Cells/ultrastructure , Surgery, Oral/methods , Adult , Humans , Male , Mesenchymal Stem Cells/ultrastructure , Middle Aged
5.
Int J Immunopathol Pharmacol ; 26(1 Suppl): 61-8, 2013.
Article in English | MEDLINE | ID: mdl-24046950

ABSTRACT

Overstrain tendonitis are common pathologies in the sport horses. Therapeutic approaches to tendon healing do not always result in a satisfactory anatomical and functional repair, and healed tendon is often characterized by functional impairment and high risk of reinjury. Recently, mesenchymal stem cells (MSCs) and platelet rich plasma (PRP) have been proposed as novel therapeutic treatments to improve the tendon repair process. MSCs are multipotent, easy to culture and being originated from adult donors do not pose ethical issues. To date, autologous MSCs have been investigated mainly in the treatment of large bone defects, cardiovascular diseases, osteogenesis imperfecta and orthopaedic injuries both in human and veterinary medicine. The clinical applications in which autologous MSCs can be used are limited because patient-specific tissue collection and cell expansion require time. For clinical applications in which MSCs should be used right away, it would be more practical to use cells collected from a donor, expanded in vitro and banked to be readily available when needed. However, there are concerns over the safety and the efficacy of allogeneic MSCs. The safety and efficacy of a therapy based on the use of allogeneic adipose tissue-derived mesenchymal stem cells (ASCs) associated to platelet rich plasma (PRP) were evaluated in 19 horses affected by acute or subacute overstrain superficial digital flexor tendonitis (SDFT). The application of allogeneic ASCs neither raised clinical sign of acute or chronic adverse tissue reactions, nor the formation of abnormal tissue in the long-term. After a follow-up of 24 months, 89.5% horses returned to their previous level of competition, while the reinjury rate was 10.5%, comparable to those recently reported for SDFT treated with autologous bone marrow derived MSCs. This study suggests that the association between allogeneic ASCs and PRP can be considered a safe and effective strategy for the treatment of SDF tendonitis in the horse.


Subject(s)
Adipose Tissue/cytology , Horse Diseases/therapy , Mesenchymal Stem Cell Transplantation , Platelet-Rich Plasma , Tendinopathy/veterinary , Animals , Horses , Tendinopathy/therapy , Transplantation, Homologous
6.
J Control Release ; 168(2): 225-37, 2013 Jun 10.
Article in English | MEDLINE | ID: mdl-23524189

ABSTRACT

Mesenchymal stem cells (MSC) have the unique ability to home and engraft in tumor stroma. These features render them potentially a very useful tool as targeted delivery vehicles which can deliver therapeutic drugs to the tumor stroma. In the present study, we investigate whether fluorescent core-shell PMMA nanoparticles (FNPs) post-loaded with a photosensitizer, namely meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) and uploaded by MSC could trigger osteosarcoma (OS) cell death in vitro upon specific photoactivation. In co-culture studies we demonstrate using laser confocal microscopy and time lapse imaging, that only after laser irradiation MSC loaded with photosensitizer-coated fluorescent NPs (TPPS@FNPs) undergo cell death and release reactive oxygen species (ROS) which are sufficient to trigger cell death of all OS cells in the culture. These results encourage further studies aimed at proving the efficacy of this novel tri-component system for PDT applications.


Subject(s)
Bone Neoplasms/drug therapy , Mesenchymal Stem Cells , Osteosarcoma/drug therapy , Photochemotherapy , Photosensitizing Agents/administration & dosage , Porphyrins/administration & dosage , Apoptosis/drug effects , Bone Neoplasms/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Drug Delivery Systems , Humans , Nanoparticles/administration & dosage , Osteosarcoma/metabolism , Reactive Oxygen Species/metabolism
7.
J Cell Physiol ; 228(6): 1229-37, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23129455

ABSTRACT

Bio-engineered scaffolds used in orthopedic clinical applications induce different tissue responses after implantation. In this study, non-stoichiometric Mg(2+) ions and stoichiometric apatites, which are used in orthopedic surgery as bone substitutes, have been assayed in vitro with human adult mesenchymal stem cells (hMSC) to evaluate cytocompatibility and osteoconductivity. hMSCs from the bone marrow aspirates of orthopedic patients were isolated and analyzed by flow cytometry for the surface markers Stro1, CD29, CD44, CD71, CD73, CD90, CD105 (positive) and CD45, CD235 (negative). The hMSC were analyzed for self-renewal capacity and for differentiation potential. The hMSC, which were grown on different biomaterials, were analyzed for (i) cytotoxicity by AlamarBlue metabolic assay, (ii) osteoconductivity by ELISA for activated focal adhesion kinase, (iii) cytoskeleton organization by fluorescence microscopy, and (iv) cell morphology which was investigated by scan electron microscopy (SEM). Results indicate that isolated cell populations agree with minimal criteria for defining hMSC cultures. Non-stoichiometric Mg(2+) and stoichiometric apatites, in granular form, represent a more favorable environment for mesenchymal stem cell adhesion and growth compared to the non-stoichiometric Mg(2+) apatite, in nano-structured paste form. This study indicates that different forms of biomaterials modulate osteoconductivity and cellular growth by differential activation focal adhesion kinase.


Subject(s)
Adult Stem Cells/metabolism , Biocompatible Materials , Bone Regeneration , Bone Substitutes , Cell Differentiation , Cell Proliferation , Mesenchymal Stem Cells/metabolism , Tissue Scaffolds , Adult Stem Cells/transplantation , Adult Stem Cells/ultrastructure , Biomarkers/metabolism , Bone Transplantation/methods , Cell Culture Techniques , Cell Shape , Cell Survival , Cells, Cultured , Cytoskeleton/metabolism , Durapatite/metabolism , Enzyme Activation , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Focal Adhesion Kinase 1/metabolism , Humans , Magnesium/metabolism , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/ultrastructure , Microscopy, Electron, Scanning , Microscopy, Fluorescence , Nanoparticles , Phosphorylation , Powders , Time Factors , Tyrosine
8.
J Microsc ; 248(1): 6-22, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22900940

ABSTRACT

Vignetting is the radial attenuation effect of the image's brightness intensity from the center of the optical axis to the edges. To perform quantitative image analyses it is mandatory to take into account this effect, intrinsic of the acquisition system. Many image processing steps, such as segmentation and object tracking, are strongly affected by vignetting and the effect becomes particularly evident in mosaicing. The most common approach to compensate the attenuation of the image's brightness intensity is to estimate the vignetting function from a homogeneous reference object, typically an empty field, and to use it to normalize the images acquired under the same microscope set-up conditions. However, several reasons lead to the use of image-based methods to estimate the vignetting function from the images themselves. In this work, we propose an effective multi-image based method suitable for real-time applications. It is designed to correct vignetting in wide field light microscopy images. The vignetting function is computed stemming from a background built incrementally from the proposed background segmentation algorithm, validated on several manually segmented images. The extensive experiments carried out using cell cultures, histological samples and synthetic images prove that our method almost always yields the best results and in worst cases are comparable to those achieved by using homogeneous reference objects.


Subject(s)
Microscopy/methods , Specimen Handling/methods , Cytological Techniques/methods , Histocytochemistry/methods , Models, Theoretical , Research Design
9.
Eur Cell Mater ; 20: 13-23, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20597062

ABSTRACT

Platelet-rich plasma (PRP) is used clinically in liquid or gel form to promote tissue repair. Because of the poor mechanical properties, conventional PRP is often difficult to handle when used in clinical settings and requires secure implantation in a specific site, otherwise when released growth factors could be washed out during an operation. In this study, we analyzed the end product of a recently developed commercially available system (FIBRINET), which is a dense pliable, platelet-rich fibrin matrix (PRFM). We characterized the mechanical properties of PRFM and tested whether PRFM releases growth factors and whether released factors induce the proliferation of mesenchymal stem cells (MSC). Mechanical properties as well as platelet distribution were evaluated in PRFM. PRFM demonstrated robust mechanical properties, with a tear elastic modulus of 937.3 +/- 314.6 kPa, stress at a break of 1476.0 +/- 526.3 kPa, and an elongation at break of 146.3 +/- 33.8 %. PRFM maintained its mechanical properties throughout the testing process. Microscopic observations showed that the platelets were localized on one side of the matrix. Elevated levels of PDGF-AA, PDGF-AB, EGF, VEGF, bFGF and TGF-beta1 were measured in the day 1-conditioned media (CM) of PRFM and growth factor levels decreased thereafter. BMP2 and BMP7 were not detectable. MSC culture media supplemented with 20% PRFM-CM stimulated MSC cell proliferation; at 24 and 48 hours the induction of the proliferation was significantly greater than the induction obtained with media supplemented with 20% foetal bovine serum. The present study shows that the production of a dense, physically robust PRFM made through high-speed centrifugation of intact platelets and fibrin in the absence of exogenous thrombin yields a potential tool for accelerating tissue repair.


Subject(s)
Fibrin/metabolism , Platelet-Rich Plasma/metabolism , Cell Proliferation , Culture Media, Conditioned , Humans , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Microscopy, Electron, Scanning , Microscopy, Fluorescence , Platelet-Derived Growth Factor/metabolism , Platelet-Rich Plasma/cytology
10.
Injury ; 39 Suppl 2: S65-72, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18804576

ABSTRACT

UNLABELLED: Massive bone allografts are frequently used in orthopaedic reconstructive surgery. However the failure rate at long term follow-up is around 25%. AIM: Stimulation of allograft incorporation. MATERIALS AND METHODS: In order to stimulate bone remodeling of an allograft we applied recombinant human osteogenic protein-1 (rh-OP-1, also know as bone morphogenetic protein-7, BMP-7) to a long bone critical size defect sheep model. In nine sheep we created a 3 cm osteoperiosteal metatarsal defect replaced with a structural allograft alone (control group, 4 animals), or an allograft added with rh-BMP-7 (BMP group, 5 animals). Radiographic, mechanical, histological and histomorphometric analysis were performed. RESULTS: X-rays in the BMP group showed a better and faster callus formation, compared to the control group within the first 8 weeks after surgery. After 16 weeks there was a higher evidence of bone remodeling in the BMP group. Radiographic healing at junction sites was more evident in the BMP group at 4, 8 and 16 weeks. Mechanical testing on screw extraction showed no statistical differences between the two groups and histomorphometry showed no difference in terms of newly formed bone inside the allograft as well. The resorption rate of the graft was higher in the BMP group in comparison to the control group. The penetration of newly formed vessels was significantly higher in the BMP group. CONCLUSIONS: These findings indicate that BMP-7 added to a structural bone allograft inducing early remodeling of the graft through stimulation of neo-angiogenesis and osteoclastic activity, without negative effects in mechanical strength and clinical outcome.


Subject(s)
Bone Morphogenetic Protein 7/administration & dosage , Bone Remodeling/drug effects , Bone Transplantation/methods , Animals , Bone Morphogenetic Protein 7/pharmacology , Bony Callus/drug effects , Disease Models, Animal , Metatarsal Bones/diagnostic imaging , Metatarsal Bones/drug effects , Metatarsal Bones/injuries , Metatarsal Bones/pathology , Metatarsal Bones/surgery , Osteotomy , Radiography , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Sheep
11.
Chir Organi Mov ; 90(1): 31-9, 2005.
Article in English, Italian | MEDLINE | ID: mdl-16422227

ABSTRACT

Bone grafting procedures are widely used to repair large defects successfully in humans, but new surgical therapies can be designed to improve allograft integration. The objective of this study was to investigate the best surgical procedure to study bone graft integration in a large animal model. An osteoperiosteal defect of 3 cm in the tibia or in the metatarsal was made in 15 adult crossbreed sheep to investigate osteo-integration of a homologous bone graft in an intercalary critical defect. DCP plates, alone or in association with Scotchcast or external fixator were used as fixation devices. The Scotchcast as was applied after surgery and left for 2 months to avoid torsion stress of the limb during the stand up movement. Metatarsal defect fixed with 7-hole DCP plate and protected with Scotchcast was the best surgical approach to avoid early or late implant failures, and provided good radiographic results after 4 months.


Subject(s)
Bone Transplantation/methods , Metatarsal Bones/surgery , Tibia/surgery , Animals , Bone Plates , Bone Transplantation/instrumentation , Casts, Surgical , Disease Models, Animal , External Fixators , Glass , Metatarsal Bones/injuries , Polyurethanes , Sheep , Tibia/injuries , Transplantation, Homologous , Treatment Outcome
12.
Int J Cancer ; 95(3): 156-61, 2001 May 20.
Article in English | MEDLINE | ID: mdl-11307148

ABSTRACT

Telomerase is a ribonucleoprotein enzyme that maintains the protective structures at the ends of eukaryotic chromosomes, called telomeres. Telomerase activity was observed and correlated with aggressiveness in different neoplasms such as breast, prostate, blood and brain cancers, among others. To investigate whether telomerase activity is an index of aggressiveness in bone and soft tissue lesions of the extremities, 66 biopsy samples from our tissue bank were studied. These samples included 43 high-grade sarcomas, 9 aggressive benign tumors and 14 totally benign lesions. The samples were collected from patients homogeneously treated at the Rizzoli Orthopaedic Institute with a follow-up ranging from 4 to 11 years (median, 7 years). A non-radioactive polymerase chain reaction-based enzyme-linked immunosorbent assay was used for the study. All tumors investigated were positive for telomerase activity. Among benign lesions, only 2 aneurysmal bone cysts showed higher telomerase activity than the cut-off point, whereas all the other benign lesions had lower activity. Our results indicate that high levels of telomerase activity in bone and soft tissue lesions correlate with more aggressive clinical behavior in patients treated with surgery alone. An interesting inverse correlation between telomerase activity and occurrence of pulmonary metastasis was detected in osteosarcoma patients treated with chemotherapy. A parallel increase of telomerase activity and malignancy was observed in the adipose and cartilagineous tissue lesions. Our data suggest that telomerase activity could be considered a marker of tumor aggressiveness for bone and soft tissue lesions. The results obtained in osteosarcoma samples suggest that low levels of telomerase activity may be predictive of the prognosis and should influence the therapeutic protocol.


Subject(s)
Bone Neoplasms/enzymology , Soft Tissue Neoplasms/enzymology , Telomerase/metabolism , Bone Neoplasms/pathology , Humans , Neoplasm Invasiveness , Soft Tissue Neoplasms/pathology
13.
Cell Mol Neurobiol ; 20(3): 409-15, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10789837

ABSTRACT

1. The strength and activity of several viral promoters in human neuroblasts were evaluated in vitro. 2. Several luciferase reporter gene constructs under the control of different viral promoters (HIV-1 LTR, HTLV-I LTR, MMTV LTR, RSV LTR, CMV, SV40), in the presence or in the absence of the viral SV40 enhancer, were transfected into two well-established human neural cell lines, including one derived from human embryonic olfactory cells (B4) and one derived from an adrenal neuroblastoma (SH-SY-5Y). The epithelial cell line HeLa was used as a control. 3. The enzymatic activity of luciferase was evaluated after normalization with an internal control. The results indicated that in the context of the reporter gene constructs, the CMV promoter alone was, overall, the most active in any tested cell line. However, addition of the SV40 enhancer to the CMV promoter abolished luciferase activity in SH-SY-5Y cells while significantly increasing luciferase expression in the CNS derived B4 fetal neuroblasts. 4. The results suggest that gene therapeutic vectors aimed to promote enzymatic activity through gene transfer into undifferentiated human neural cells are feasible. However, since differences in promoter activity in neuroectodermal-derived cells are very relevant, gene construct variants should be considered to optimize the system.


Subject(s)
Gene Expression Regulation, Viral , Gene Transfer Techniques , Neuroblastoma , Plasmids , Promoter Regions, Genetic/genetics , Avian Sarcoma Viruses/genetics , Cytomegalovirus/genetics , Genes, Reporter , Genetic Engineering , HIV-1/genetics , HeLa Cells , Human T-lymphotropic virus 1/genetics , Humans , Luciferases/genetics , Mammary Tumor Virus, Mouse/genetics , Simian virus 40/genetics , Terminal Repeat Sequences
14.
Int J Mol Med ; 4(6): 593-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10567667

ABSTRACT

Lipoma is one of the most common benign mesenchymal tumors. Its ability to trigger an angiogenic response is a critical step for its growth. Because adipose tissue serves as an important conduit for the vasculature, it is conceivable that the angiogenic properties of this tissue may modulate the growth of the vasculature in a paracrine manner. We investigated in vivo the angiogenic potential of bioptic fragments of human lipoma by using the chick embryo chorioallantoic membrane (CAM), a useful model for such an investigation. The angiogenic response in pathological and control implants was assessed on histologic sections by a morphometric method, 96 h after grafting. Results showed that pathological samples were surrounded by numerous allantoic vessels with a radially arranged pattern around the implant. The vascular counts in the CAMs treated with lipoma implants were comparable to that of FGF-2. The role played in vasoproliferative response by angiogenic cytokines (FGF-2, VEGF) released by adipocytes, by endogenous cytokines, such as FGF-2, stored in the CAM extracellular matrix and by angiogenic growth factors released by perivascular mononuclear cells around the newly-formed blood vessels, were supported by this study.


Subject(s)
Allantois/blood supply , Chorion/blood supply , Lipoma/blood supply , Neovascularization, Pathologic/etiology , Adult , Aged , Animals , Chick Embryo , Child, Preschool , Female , Fibroblast Growth Factor 2/pharmacology , Humans , Lipoma/pathology , Male , Middle Aged , Neoplasm Transplantation
15.
Eur J Cancer ; 33(12): 2068-70, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9516854

ABSTRACT

In neuroblastoma tumours, the expression of high levels of trk-A mRNA, which encodes the high-affinity nerve growth factor (NGF) receptor, is associated with good prognosis. Constitutive expression of brain-derived neurotrophic factor (BDNF) and variable expression of its receptor trk-B are frequently detected in tumours from patients with a poor prognosis. To evaluate the biological consequences of activation of the trk-A or trk-B signal transduction pathways in neuroblastoma cells, the trk-A or trk-B gene was transfected into the trk negative 15N neuroblastoma cell line. Clones expressing trk-A or trk-B were treated with specific ligands and evaluated for growth and differentiation. Both ligands induced neurite extension. Treatment of the 15N-trk-A clones with NGF inhibited proliferation (80-90% decrease), while treatment of the 15N-trk-B clone with BDNF had no effect (< 10% decrease). NGF-induced growth inhibition was concentration dependent. Such studies indicate that differential trk expression may affect the biology of neuroblastoma tumours and contribute to differences in the clinical course of patients.


Subject(s)
Neuroblastoma/metabolism , Neuroblastoma/pathology , Proto-Oncogene Proteins/drug effects , RNA, Messenger/metabolism , Receptor Protein-Tyrosine Kinases/drug effects , Receptors, Nerve Growth Factor/drug effects , Signal Transduction/physiology , Brain-Derived Neurotrophic Factor/pharmacology , Cell Division , Humans , Nerve Growth Factors/pharmacology , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor, trkA , Receptor, trkB , Receptors, Nerve Growth Factor/genetics , Transfection , Tumor Cells, Cultured
16.
Cancer Res ; 56(16): 3737-42, 1996 Aug 15.
Article in English | MEDLINE | ID: mdl-8706017

ABSTRACT

Brain-derived neurotrophic factor (BDNF) and its receptors are necessary for the survival and development of many neuronal cells. Because BDNF and TrkB are expressed in many poor-prognosis neuroblastoma (NB) tumors, we evaluated the role of BDNF in affecting sensitivity to chemotherapeutic agents. We investigated the effects of activation of the BDNF-TrkB signal transduction pathway in two NB cell lines, 15N and SY5Y. 15N cells lack the high-affinity receptor p145TrkB and express BDNF; 15N cells were used along with 15N-TrkB cells, a subline transfected with a TrkB expression vector. In cytotoxicity assays, 15N-TrkB cells were consistently 1.4-2 fold more resistant to vinblastine than 15N cells. Drug accumulation assays showed a 50% reduction in[3H]vinblastine accumulation in 15N-TrkB cells compared with control 15N cells. Addition of 30 ng/ml BDNF resulted in a reduction to 46% of control in 15N cells and a reduction to 28% of control in 15N-TrkB cells. SY5Y cells were chosen as a second model because they lack both endogenous BDNF and TrkB expression. p145TrkB expression is induced by 1 nM retinoic acid. Vinblastine accumulation was not significantly affected by 1 nM retinoic acid in SY5Y cells. Addition of 30 ng/ml BDNF decreased [3H]vinblastine accumulation to 58% of control in SY5Y cells and decreased [3H]vinblastine accumulation to 62% of control in TrkB-expressing SY5Y cells. Although an increase in BDNF expression in seen in multidrug-resistant sublines of SY5Y and BE(2)-C NB cells, the protective effect of BDNF in vinblastine toxicity may be unrelated to mdr-1, because the activity of other agents transported by P-glycoprotein was not affected. There was no increase in mdr-1 expression in 1 nM RA SY5Y cells and 15N-TrkB cells, as assessed by Northern blot analysis. In addition to the effects of BDNF on vinblastine cytotoxicity and accumulation, there was an inhibition in the ability of vinblastine to depolymerize tubulin in BDNF-treated cells. Thus, BDNF and TrkB may partially rescue NB cells from vinblastine toxicity and thereby may contribute to a more chemoresistant phenotype.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Nerve Tissue Proteins/pharmacology , Neuroblastoma/drug therapy , Vinblastine/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Brain-Derived Neurotrophic Factor , Drug Resistance , Humans , Nerve Tissue Proteins/genetics , RNA, Messenger/analysis , Tretinoin/pharmacology , Tubulin/metabolism , Tumor Cells, Cultured , Vinblastine/pharmacokinetics
17.
J Biol Chem ; 270(42): 24725-31, 1995 Oct 20.
Article in English | MEDLINE | ID: mdl-7559588

ABSTRACT

Trk receptors are a family of genes implicated in the survival, differentiation, and growth of certain neurons and tumors of the nervous system. A better understanding of the regulation of Trk receptors is relevant for developmental and oncological studies. Human neuroblastoma (NB) cell lines constitutively express low levels of TrkA mRNA, while TrkB mRNA is not readily detectable. Differentiation of NB cells is accompanied by a differential modulation of Trk expression in human NB cells. Nanomolar concentrations of RA induce a stable increase of TrkB mRNA. A transient induction of TrkA mRNA levels requires micromolar concentrations of RA. Induction of both TrkA and TrkB mRNA does not require new protein synthesis. However, RA-induced TrkB mRNA expression is transcriptionally regulated, while the transient RA-induced increase of TrkA mRNA is a consequence of extended mRNA stability. Interferon gamma (IFN-gamma) selectively increases TrkA mRNA without affecting TrkB mRNA levels. Similar to RA, IFN-gamma does not modify the transcriptional rate of TrkA mRNA, but rather increases TrkA mRNA stability. Thus, RA and IFN-gamma differentially regulate TrkA or TrkB expression in the same cell type by predominantly transcriptional (TrkB) or post transcriptional (TrkA) mechanisms. Such experiments indicate the complexity of Trk mRNA regulation and also indicate compounds that may affect neurotrophin responsiveness in developing neural cells.


Subject(s)
Interferon-gamma/pharmacology , Proto-Oncogene Proteins/drug effects , Receptor Protein-Tyrosine Kinases/drug effects , Receptors, Nerve Growth Factor/drug effects , Tretinoin/pharmacology , Gene Expression Regulation/drug effects , Humans , Neuroblastoma/metabolism , Phosphorylation , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , RNA, Messenger/analysis , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, trkA , Receptor, trkB , Receptors, Nerve Growth Factor/genetics , Receptors, Nerve Growth Factor/metabolism , Tumor Cells, Cultured
18.
Cell Death Differ ; 1(1): 49-58, 1994 Jul.
Article in English | MEDLINE | ID: mdl-17180006

ABSTRACT

Retinoic Acid (RA) has been shown to control growth and induce differentiation in a number of human neuroblastoma (NB) cell lines. However, a number of NB cell lines may be termed resistant to RA as they fail to growth arrest and differentiate. In studying the mechanism mediating RA-resistance, we noted that invariably RA-resistant NB cell lines constitutively express Insulin-like Growth Factor 2 (IGF2) (Gaetano, 1991b). The NB cell line LAN-1-15N (15N) represented an interesting model in which to study the development of RA-resistance as initially 15N cells are growth arrested by RA, however with prolonged culture (8-10 days) cells begin to proliferate. Coincidentally, RA induces IGF2 mRNA and protein secretion in 15N NB cells (Matsumoto, 1992). In this study we isolated RA-resistant 15N cell lines and analyzed their growth properties and changes in cell cycle related (cdc2, cdk2, cyclins A, B, D and E) and early response (fos and jun) gene expression to evaluate the role IGF2 may play in mediating RA resistance. We found that exogenous IGF2 stimulates growth in 15N and is capable of altering RA induced inhibition of NB cell growth. Finally we show that by blocking the Insulin-like Growth Factor Receptor (IGF1(R)) with a monoclonal antibody (alpha-IR3) in the presence of RA the growth of RAR cell lines could be completely blocked. These data are consistent with the concept that signals by IGF2 and transduced via the IGF1(R) can mediate resistance to the growth inhibiting properties of RA.

20.
Neuron ; 11(2): 321-31, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8394722

ABSTRACT

Retinoic acid (RA) induces the neuronal differentiation of many human neuroblastoma cell lines. In this study, we show that RA treatment of neuroblastoma cells induces the expression of TrkB, the receptor for the neurotrophins BDNF, NT-3, and NT-4/5. BDNF addition to RA-treated SH-SY5Y neuroblastoma cells stimulated the tyrosine phosphorylation of TrkB and neuronal differentiation. RA treatment of KCNR neuroblastoma cells, which constitutively express BDNF mRNA, resulted in the expression of TrkB and differentiation in the absence of added BDNF. Finally, in 15N neuroblastoma cells, which express BDNF mRNA but do not differentiate in response to RA, RA induced only a truncated form of TrkB. 15N cells transfected with full-length TrkB differentiated in the absence of RA. These results indicate that RA induces the neuronal differentiation of neuroblastoma cells by modulating the expression of neurotrophin receptors.


Subject(s)
Gene Expression Regulation/drug effects , Nerve Tissue Proteins/pharmacology , Neuroblastoma/pathology , Proto-Oncogene Proteins/genetics , Tretinoin/pharmacology , Cell Differentiation/drug effects , Humans , Nerve Growth Factors/pharmacology , Nerve Tissue Proteins/genetics , Neurons/pathology , Peptide Fragments/metabolism , Phosphorylation/drug effects , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , RNA, Messenger/metabolism , Receptor, trkA , Receptors, Cell Surface/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/pathology , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL